A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(22 sites)

United States

University of California Irvine, Orange, California

Stanford University, Palo Alto, California

University of Colorado, Denver, Colorado

University of Florida, Gainesville, Florida

University of Iowa, Iowa City, Iowa